4-Methylquinazoline Derivatives as Selective PI3Kδ Inhibitors for Acute Lung Injury

A dataset from 2026 describes a novel series of 4-methylquinazoline derivatives designed as potent and selective PI3Kδ inhibitors. The data, authored by Deyu Wu, includes structural information for a lead compound exhibiting single-digit nanomolar potency and selectivity over other PI3K isoforms. It also contains results from murine models of LPS-induced acute lung injury and septic lung injury.

Use Cases

• Structure-activity relationship (SAR) analysis based on the series of 4-methylquinazoline derivatives
• Computational modeling of PI3Kδ inhibitor binding based on the provided PDB files
• Evaluating pharmacokinetic properties of novel drug candidates based on the described favorable properties
• Assessing therapeutic efficacy in inflammatory lung injury models based on the murine model results

Strengths

• Includes data on a lead compound with single-digit nanomolar potency against PI3Kδ
• Describes compound selectivity over other class I PI3K isoforms
• Contains results from in vivo murine models of LPS-induced and septic lung injury

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data may reflect experimental bias inherent to the specific research project

Provenance

Source

figshare

Collection Method

Likely contains experimental data from structure-based drug design, synthesis, and in vitro/in vivo testing.

Freshness

Last updated 2026-05-24 13:08:35